Filing Flows › Zomedica (ZOMDF) › Q2 2026 › vs Q2 2025
Zomedica (ZOMDF) Q2 2026 vs Q2 2025 (year over year)
Zomedica's revenue rose $2.5M (+37%) from $7.0M in Q2 2025 to $9.5M in Q2 2026. The biggest changes: Consumables +$1.4M (+26%); Capital +$186K (+11%); Other +$26K (+137%).
Zomedica, Q2 2026: revenue $9.5M (+37% year over year), operating margin -42.9%, net loss $3.8M, operating cash flow −$2.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Consumables | $6.6M | $5.3M | $1.4M | +26% |
| Capital | $1.8M | $1.7M | $186K | +11% |
| Other | $45K | $19K | $26K | +137% |
| Revenue | $9.5M | $7.0M | $2.5M | +37% |
| Other income, net | $344K | $649K | −$305K | -47% |
| Net loss | $3.8M | $7.4M | −$3.6M | -49% |
| Costs & expenses | $13.6M | $15.0M | −$1.4M | -9% |
| Operating costs | $13.6M | $15.0M | −$1.4M | -9% |
| Income tax | $26K | $12K | $14K | +117% |
| Cost of revenue | $3.5M | $2.3M | $1.2M | +51% |
| Research & development | $1.1M | $1.9M | −$816K | -43% |
| Sales & marketing | $3.7M | $4.7M | −$978K | -21% |
| General & admin | $5.4M | $6.2M | −$783K | -13% |
| Operating cash sources | $4.5M | $7.6M | −$3.2M | -41% |
| Depreciation & amortization | $1.8M | $1.9M | −$78K | -4% |
| Share-based compensation | $69K | $260K | −$191K | -73% |
| Cash used in operations | $2.6M | $5.4M | −$2.9M | -53% |
| Net loss absorbed | $3.8M | $7.4M | −$3.6M | -49% |
| Working capital & other | $698K | $225K | $473K | +210% |
Questions
How much did Zomedica's revenue grow year over year in Q2 2026?
Zomedica's revenue rose $2.5M (+37%) from $7.0M in Q2 2025 to $9.5M in Q2 2026.
What drove Zomedica's revenue change in Q2 2026?
Consumables +$1.4M (+26%); Capital +$186K (+11%); Other +$26K (+137%).